Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA.
Viruses. 2010 Aug;2(8):1510-1529. doi: 10.3390/v2081510. Epub 2010 Jul 27.
The emergence of pandemic H1N1 influenza viruses in April 2009 and the continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs are currently limited to the neuraminidase inhibitors (oseltamivir and zanamivir) and to M2 ion channel blockers (amantadine and rimantadine), although resistance to the latter class develops rapidly. Potential targets for the development of new anti-influenza agents include the viral polymerase (and endonuclease), the hemagglutinin, and the non-structural protein NS1. The limitations of monotherapy and the emergence of drug-resistant variants make combination chemotherapy the logical therapeutic option. Here we review the experimental data on combination chemotherapy with currently available agents and the development of new agents and therapy targets.
2009 年 4 月，大流行 H1N1 流感病毒的出现和高致病性 H5N1 流感病毒的持续演变，突显了开发新型抗人流感药物的紧迫性。目前抗流感药物仅限于神经氨酸酶抑制剂（奥司他韦和扎那米韦）和 M2 离子通道阻滞剂（金刚烷胺和金刚乙胺），尽管后者的耐药性迅速发展。开发新的抗流感药物的潜在靶点包括病毒聚合酶（和内切酶）、血凝素和非结构蛋白 NS1。单一疗法的局限性和耐药变异株的出现使得联合化疗成为合理的治疗选择。本文综述了现有药物联合化疗的实验数据以及新药物和治疗靶点的开发。
